Copyright
©The Author(s) 2022.
World J Clin Cases. Nov 6, 2022; 10(31): 11240-11251
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11240
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11240
Figure 1 Schematic summary of intestinal microbiota dysbiosis responsible for the pathogenesis of metabolically associated fatty liver disease.
MAFLD: Metabolically associated fatty liver disease; PAMPs: Pathogen-associated molecular patterns; ANGPL4: Angiopoietin-related protein 4; SCFAs: Short-chain fatty acids.
- Citation: Wang JS, Liu JC. Intestinal microbiota in the treatment of metabolically associated fatty liver disease. World J Clin Cases 2022; 10(31): 11240-11251
- URL: https://www.wjgnet.com/2307-8960/full/v10/i31/11240.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i31.11240